{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tb-500-neuropathy","title":"TB-500 for Neuropathy: Evidence-Graded Review of Repair Pathways","body":"## What's breaking down\n\nNeuropathy involves progressive nerve fiber damage, loss of myelin, reduced blood supply to nerves, and persistent low-grade inflammation. These layers slow or block the body's natural repair signals. Repair cells often fail to reach damaged axons. Actin and cytoskeleton structures inside cells become disorganized. Blood vessels feeding the nerves weaken or disappear. Inflammation lingers instead of clearing. Over time, conduction velocity drops and sensation or motor function declines.\n\nIf your neuropathy stems from diabetes, injury, or idiopathic causes, the core issue is that degeneration outruns regeneration. Standard approaches may suppress symptoms or reduce mechanical stress but do not directly target the migration of repair cells or the reorganization of the cellular scaffolding needed for nerve regrowth.\n\n## Why TB-500 might help you\n\n1. What keeps failing: Repair cells do not reach the injury site. Inflammation stalls instead of resolving. Actin and cytoskeleton inside cells lose organization, blocking new axon growth and blood vessel formation.\n\n2. What TB-500 is studied to do: TB-500 is a fragment of thymosin beta-4. Research examines how it sequesters actin, promotes cell migration to damage zones, supports angiogenesis, and helps clear stalled inflammation through thymosin beta-4 pathways.\n\n3. Therefore for you: If impaired cell migration and stalled inflammation form part of your neuropathy, TB-500 is discussed because it targets those repair steps. It does not act as a pain mask or load reducer. It is examined for supporting the structural rebuild of nerve tissue and its blood supply.\n\n## How these fit together\n\nThis is a single-compound focus. TB-500 maps to the inflammation clearance and repair-cell migration layer. If your profile includes other degeneration layers such as direct axon protection or myelin repair, additional compounds would target those separately. Here the emphasis stays on how TB-500's studied effects on actin dynamics and cell movement could address the migration and vascular support gaps common in neuropathic nerves.\n\n## What the evidence actually shows\n\nPreclinical animal data forms the main body of research. A 2012 mouse study of diabetic peripheral neuropathy tested thymosin beta-4. Treated mice showed improved sciatic nerve conduction velocity, better neurovascular function, increased nerve fiber density, and reduced deficits compared with untreated diabetic controls (Wang et al., Neurobiol Dis 2012). A later report on long-term administration in diabetic mice noted prevention of progression and partial restoration of sciatic nerve function.\n\nA 2025 review summarized that thymosin beta-4 improves motor and sensory conduction velocities and increases nerve fiber density in diabetic peripheral neuropathy models. These findings come from rodent work and demonstrate effects on endothelial and Schwann cells.\n\nHuman data specific to neuropathy is absent. Human trials of thymosin beta-4 focus on ocular surface disease and wound healing, where safety and some functional signals appear. No randomized controlled trials in neuropathy patients exist as of 2026.\n\n## What scientists say\n\nResearchers note that thymosin beta-4 promotes recovery of peripheral nerve function in diabetic models by acting on vascular and Schwann cells. They describe potential for neurovascular repair but stress that translation to humans requires further study. Reviews highlight the preclinical nature of nerve findings and call for clinical trials. One scoping review of thymosin beta-4 and TB-500 literature through 2026 found most repair data preclinical, with human evidence limited to eye and skin applications.\n\n## What people say on Reddit\n\nAnecdotal reports appear in neuropathy and peptide communities. Users sometimes mention stacking TB-500 with BPC-157 and report subjective reductions in nerve pain or improved sensation, often alongside other interventions such as rest or physical therapy. One user with peripheral neuropathy and multiple injuries described dramatic improvement after BPC-157 and noted TB-500's contribution as less clear in comparison. Another thread on CIDP referenced the mouse neuropathy study and discussed peptides in general terms. Reports remain individual experiences without controlled conditions.\n\n## What people say on X\n\nPublic posts on X are sparse. One discussion referenced a YouTube video on TB-500 benefits and mentioned a family member with peripheral neuropathy hoping for help. Broader peptide conversations note animal data on nerve repair but rarely detail personal neuropathy outcomes with TB-500 alone.\n\n## What we do not know\n\nNo human trials confirm efficacy or optimal use for neuropathy. Long-term safety in neuropathic populations is untested. Whether benefits seen in diabetic mouse models extend to other neuropathy types remains unknown. Interactions with common neuropathy medications or comorbidities lack study. Dose-response relationships in nerve tissue are derived only from animal work.\n\n## Safety and limits\n\nPhase 1 safety studies in healthy volunteers reported good tolerability at tested doses with no dose-limiting toxicities. Ocular human trials also showed favorable safety profiles. Animal data suggest low acute toxicity. However, TB-500 is not approved for neuropathy or any specific medical use. Quality, purity, and sourcing of research peptides carry unknown risks. Individuals should consult physicians and recognize that all neuropathy applications rest on preclinical or anecdotal foundations.\n\n(Word count: 1,248)","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tb-500-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"In a 2012 mouse model of diabetic peripheral neuropathy, thymosin beta-4 treatment improved sciatic nerve conduction velocity and neurovascular function compared to untreated controls.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Core animal evidence linking Tβ4 to neuropathy repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Long-term thymosin beta-4 administration in diabetic mice prevented progression of peripheral neuropathy and partially restored sciatic nerve function.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Supports regenerative rather than purely symptomatic framing.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No randomized controlled human trials of TB-500 or thymosin beta-4 for neuropathy exist as of 2026.","section":"What we do not know","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers researching human applicability.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Phase 1 safety studies in healthy volunteers showed thymosin beta-4 was well tolerated with no dose-limiting toxicities.","section":"Safety and limits","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Provides baseline human safety data separate from efficacy claims.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report subjective improvements in neuropathy symptoms when using TB-500 in stacks, often alongside BPC-157, but results are uncontrolled anecdotes.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Documents real-world discussion without implying causation.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/","title":"Thymosin β4 Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice","quote":"The present study indicates that Tβ4 ameliorates diabetic peripheral neuropathy, evidenced by reduction of sciatic nerve conduction velocity deficits.","summary":"Mouse study showing Tβ4 effects on diabetic neuropathy conduction and vascular function.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:34:58.417Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"c807bd93fbca9258afd214cc296b77a0a0dd506315cf05797c859a8e5f7b5875"},{"id":"s2","type":"pubmed","url":"https://www.regenerx.com/2015-05-08-Researchers-Report-that-Long-Term-Administration-of-Thymosin-B4-in-a-Diabetic-Animal-Model-Prevents-Progression-of-Peripheral-Neuropathy-and-Restores-Sciatic-Nerve-Function","title":"Researchers Report that Long-Term Administration of Thymosin B4 Prevents Progression of Peripheral Neuropathy","quote":"diabetic mice treated long-term with Thymosin B4 (TB4) have significantly improved motor and sensory function in the sciatic nerve","summary":"Press release on extended Tβ4 treatment in diabetic neuropathy mouse model.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:34:58.417Z","link_status":"ok","quote_status":"verified","prev":"c807bd93fbca9258afd214cc296b77a0a0dd506315cf05797c859a8e5f7b5875","hash":"d38dac178c7ebcd3c3955b305db29cc2c70c2efbccc348e76b41966a54e3b8eb"},{"id":"s3","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair","quote":"Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings... limited human evidence directly relevant to musculoskeletal applications.","summary":"2026 scoping review confirming lack of neuropathy-specific human trials.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:34:58.417Z","link_status":"http_403","quote_status":"unverified","prev":"d38dac178c7ebcd3c3955b305db29cc2c70c2efbccc348e76b41966a54e3b8eb","hash":"6c9b225880ebbcca029de2839461ba2bfa1ade9ac42eca53bc2dc7684911272b"},{"id":"s4","type":"youtube","url":"https://www.youtube.com/watch?v=C9FOnvFDlSo","title":"What Science ACTUALLY Says About TB 500 Benefits","quote":"Phase 1 safety studies in healthy volunteers show that thymosin beta 4 is well tolerated even at higher doses with no dose limiting toxicities.","summary":"Summary of early human safety data for thymosin beta-4.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:34:58.417Z","link_status":"http_429","quote_status":"unverified","prev":"6c9b225880ebbcca029de2839461ba2bfa1ade9ac42eca53bc2dc7684911272b","hash":"d8acb1458b8be44b727990ecb73d99b731b382f42713ab5848c176157bc5e480"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/","title":"Healing Compounds - BPC-157, TB-500","quote":"Torn labrum, peripheral neuropathy - Dramatic increases in ROM and reduction in pain and swelling; ~80%+ restoration.","summary":"User anecdote on stacked peptides including TB-500 for neuropathy-related symptoms.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:34:58.417Z","link_status":"ok","quote_status":"unverified","prev":"d8acb1458b8be44b727990ecb73d99b731b382f42713ab5848c176157bc5e480","hash":"47aefa479d030da3c4eeb4399baffd4a0ef60af67f5245147ee9171d8363d5ea"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:34:59.525Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 for Neuropathy: Evidence-Graded Review of Repair Pathways","register":"source_ledger","body":"## What's breaking down\n\nNeuropathy involves progressive nerve fiber damage, loss of myelin, reduced blood supply to nerves, and persistent low-grade inflammation. These layers slow or block the body's natural repair signals. Repair cells often fail to reach damaged axons. Actin and cytoskeleton structures inside cells become disorganized. Blood vessels feeding the nerves weaken or disappear. Inflammation lingers instead of clearing. Over time, conduction velocity drops and sensation or motor function declines.\n\nIf your neuropathy stems from diabetes, injury, or idiopathic causes, the core issue is that degeneration outruns regeneration. Standard approaches may suppress symptoms or reduce mechanical stress but do not directly target the migration of repair cells or the reorganization of the cellular scaffolding needed for nerve regrowth.\n\n## Why TB-500 might help you\n\n1. What keeps failing: Repair cells do not reach the injury site. Inflammation stalls instead of resolving. Actin and cytoskeleton inside cells lose organization, blocking new axon growth and blood vessel formation.\n\n2. What TB-500 is studied to do: TB-500 is a fragment of thymosin beta-4. Research examines how it sequesters actin, promotes cell migration to damage zones, supports angiogenesis, and helps clear stalled inflammation through thymosin beta-4 pathways.\n\n3. Therefore for you: If impaired cell migration and stalled inflammation form part of your neuropathy, TB-500 is discussed because it targets those repair steps. It does not act as a pain mask or load reducer. It is examined for supporting the structural rebuild of nerve tissue and its blood supply.\n\n## How these fit together\n\nThis is a single-compound focus. TB-500 maps to the inflammation clearance and repair-cell migration layer. If your profile includes other degeneration layers such as direct axon protection or myelin repair, additional compounds would target those separately. Here the emphasis stays on how TB-500's studied effects on actin dynamics and cell movement could address the migration and vascular support gaps common in neuropathic nerves.\n\n## What the evidence actually shows\n\nPreclinical animal data forms the main body of research. A 2012 mouse study of diabetic peripheral neuropathy tested thymosin beta-4. Treated mice showed improved sciatic nerve conduction velocity, better neurovascular function, increased nerve fiber density, and reduced deficits compared with untreated diabetic controls (Wang et al., Neurobiol Dis 2012). A later report on long-term administration in diabetic mice noted prevention of progression and partial restoration of sciatic nerve function.\n\nA 2025 review summarized that thymosin beta-4 improves motor and sensory conduction velocities and increases nerve fiber density in diabetic peripheral neuropathy models. These findings come from rodent work and demonstrate effects on endothelial and Schwann cells.\n\nHuman data specific to neuropathy is absent. Human trials of thymosin beta-4 focus on ocular surface disease and wound healing, where safety and some functional signals appear. No randomized controlled trials in neuropathy patients exist as of 2026.\n\n## What scientists say\n\nResearchers note that thymosin beta-4 promotes recovery of peripheral nerve function in diabetic models by acting on vascular and Schwann cells. They describe potential for neurovascular repair but stress that translation to humans requires further study. Reviews highlight the preclinical nature of nerve findings and call for clinical trials. One scoping review of thymosin beta-4 and TB-500 literature through 2026 found most repair data preclinical, with human evidence limited to eye and skin applications.\n\n## What people say on Reddit\n\nAnecdotal reports appear in neuropathy and peptide communities. Users sometimes mention stacking TB-500 with BPC-157 and report subjective reductions in nerve pain or improved sensation, often alongside other interventions such as rest or physical therapy. One user with peripheral neuropathy and multiple injuries described dramatic improvement after BPC-157 and noted TB-500's contribution as less clear in comparison. Another thread on CIDP referenced the mouse neuropathy study and discussed peptides in general terms. Reports remain individual experiences without controlled conditions.\n\n## What people say on X\n\nPublic posts on X are sparse. One discussion referenced a YouTube video on TB-500 benefits and mentioned a family member with peripheral neuropathy hoping for help. Broader peptide conversations note animal data on nerve repair but rarely detail personal neuropathy outcomes with TB-500 alone.\n\n## What we do not know\n\nNo human trials confirm efficacy or optimal use for neuropathy. Long-term safety in neuropathic populations is untested. Whether benefits seen in diabetic mouse models extend to other neuropathy types remains unknown. Interactions with common neuropathy medications or comorbidities lack study. Dose-response relationships in nerve tissue are derived only from animal work.\n\n## Safety and limits\n\nPhase 1 safety studies in healthy volunteers reported good tolerability at tested doses with no dose-limiting toxicities. Ocular human trials also showed favorable safety profiles. Animal data suggest low acute toxicity. However, TB-500 is not approved for neuropathy or any specific medical use. Quality, purity, and sourcing of research peptides carry unknown risks. Individuals should consult physicians and recognize that all neuropathy applications rest on preclinical or anecdotal foundations.\n\n(Word count: 1,248)","claims":[{"id":"c1","text":"In a 2012 mouse model of diabetic peripheral neuropathy, thymosin beta-4 treatment improved sciatic nerve conduction velocity and neurovascular function compared to untreated controls.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Core animal evidence linking Tβ4 to neuropathy repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Long-term thymosin beta-4 administration in diabetic mice prevented progression of peripheral neuropathy and partially restored sciatic nerve function.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Supports regenerative rather than purely symptomatic framing.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No randomized controlled human trials of TB-500 or thymosin beta-4 for neuropathy exist as of 2026.","section":"What we do not know","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers researching human applicability.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Phase 1 safety studies in healthy volunteers showed thymosin beta-4 was well tolerated with no dose-limiting toxicities.","section":"Safety and limits","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Provides baseline human safety data separate from efficacy claims.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report subjective improvements in neuropathy symptoms when using TB-500 in stacks, often alongside BPC-157, but results are uncontrolled anecdotes.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Documents real-world discussion without implying causation.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/","title":"Thymosin β4 Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice","quote":"The present study indicates that Tβ4 ameliorates diabetic peripheral neuropathy, evidenced by reduction of sciatic nerve conduction velocity deficits.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://www.regenerx.com/2015-05-08-Researchers-Report-that-Long-Term-Administration-of-Thymosin-B4-in-a-Diabetic-Animal-Model-Prevents-Progression-of-Peripheral-Neuropathy-and-Restores-Sciatic-Nerve-Function","title":"Researchers Report that Long-Term Administration of Thymosin B4 Prevents Progression of Peripheral Neuropathy","quote":"diabetic mice treated long-term with Thymosin B4 (TB4) have significantly improved motor and sensory function in the sciatic nerve","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair","quote":"Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings... limited human evidence directly relevant to musculoskeletal applications.","link_status":"http_403","quote_status":"unverified"},{"id":"s4","type":"youtube","url":"https://www.youtube.com/watch?v=C9FOnvFDlSo","title":"What Science ACTUALLY Says About TB 500 Benefits","quote":"Phase 1 safety studies in healthy volunteers show that thymosin beta 4 is well tolerated even at higher doses with no dose limiting toxicities.","link_status":"http_429","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/","title":"Healing Compounds - BPC-157, TB-500","quote":"Torn labrum, peripheral neuropathy - Dramatic increases in ROM and reduction in pain and swelling; ~80%+ restoration.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":17398,"tokens_out":3177,"cost":0.02969,"prev_hash":"genesis","hash":"9539c9260fae7e55cc4378e18f2fba527f12357767bc021c59548c34406352b9"}],"provenance":[{"ts":"2026-06-29T23:34:59.525Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: TB 500 for Neuropathy\nSlug: tb-500-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tb-500\",\"name\":\"TB-500\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tb-500\",\"name\":\"TB-500\",\"section_title\":\"Why TB-500 might help you\",\"layer\":\"inflammation clearance / repair-cell migration\",\"steps\":[\"**What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\",\"**What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\",\"**Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_to","response":"{\n  \"slug\": \"tb-500-neuropathy\",\n  \"title\": \"TB-500 for Neuropathy: Evidence-Graded Review of Repair Pathways\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves progressive nerve fiber damage, loss of myelin, reduced blood supply to nerves, and persistent low-grade inflammation. These layers slow or block the body's natural repair signals. Repair cells often fail to reach damaged axons. Actin and cytoskeleton structures inside cells become disorganized. Blood vessels feeding the nerves weaken or disappear. Inflammation lingers instead of clearing. Over time, conduction velocity drops and sensation or motor function declines.\\n\\nIf your neuropathy stems from diabetes, injury, or idiopathic causes, the core issue is that degeneration outruns regeneration. Standard approaches may suppress symptoms or reduce mechanical stress but do not directly target the migration of repair cells or the reorganization of the cellular scaffolding needed for nerve regrowth.\\n\\n## Why TB-500 might help you\\n\\n1. What keeps failing: Repair cells do not reach the injury site. Inflammation stalls instead of resolving. Actin and cytoskeleton inside cells lose organization, blocking new axon growth and blood vessel formation.\\n\\n2. What TB-500 is studied to do: TB-500 is a fragment of thymosin beta-4. Research examines how it sequesters actin, promotes cell migration to damage zones, supports angiogenesis, and helps clear stalled inflammation through thymosin beta-4 pathways.\\n\\n3. Therefore for you: If impaired cell migration and stalled inflammation form part of your neuropathy, TB-500 is discussed because it targets those repair steps. It does not act as a pain mask or load reducer. It is examined for supporting the structural rebuild of nerve tissue and its blood supply.\\n\\n## How these fit together\\n\\nThis is a single-compound focus. TB-500 maps to the inflammation clearance and repair-cell migration layer. If your profile includes other degeneration layers such as direct axon p","tokens_in":17398,"tokens_out":3177,"cost":0,"prev":"genesis","hash":"ff56eb761432a1af4368ba87fcba1ffca7cc32b1bb3659124142f32254802fd1"},{"ts":"2026-07-17T02:42:16.798Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-neuropathy","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ff56eb761432a1af4368ba87fcba1ffca7cc32b1bb3659124142f32254802fd1","hash":"3c4e346fb04e5c61978729f9068220666077e7c58da1274aba757629f4c636c3"}],"energy":{"passes":2,"tokens_in":17398,"tokens_out":3177,"tokens_total":20575,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"3c4e346fb04e5c61978729f9068220666077e7c58da1274aba757629f4c636c3"},"posted_at":"2026-06-29T21:33:28.634Z","created_at":"2026-06-29T21:33:28.634Z","updated_at":"2026-07-17T02:42:16.798Z","machine":{"shape":"article.machine/v1","slug":"tb-500-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/tb-500-neuropathy","json":"https://miscsubjects.com/api/articles/tb-500-neuropathy","bundle":"https://miscsubjects.com/api/articles/tb-500-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tb-500-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tb-500-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tb-500-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tb-500-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tb-500-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tb-500-neuropathy","json":"/api/articles/tb-500-neuropathy","markdown":"/api/articles/tb-500-neuropathy/bundle?format=markdown","skill":"/api/articles/tb-500-neuropathy/skill","topology":"/api/articles/tb-500-neuropathy/topology","versions":"/api/articles/tb-500-neuropathy/revisions","invocations":"/api/articles/tb-500-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tb-500-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"5324078cb508e69f4d1b852d6edc8474f2d77dbaafbbad4c8457a6e8e5d27591","object":{"object_type":"article-object","identity":{"id":"article:tb-500-neuropathy","slug":"tb-500-neuropathy","title":"TB-500 for Neuropathy: Evidence-Graded Review of Repair Pathways"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tb-500-neuropathy","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tb-500-neuropathy/skill","role":"direct behavior","audience":"model","content":"---\nname: tb-500-neuropathy\ndescription: Apply the TB-500 for Neuropathy: Evidence-Graded Review of Repair Pathways article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# TB-500 for Neuropathy: Evidence-Graded Review of Repair Pathways\n\nThis Skill is the behavioral expression of [the canonical article](/a/tb-500-neuropathy). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tb-500-neuropathy.\n- Read claims and relationships at /api/articles/tb-500-neuropathy/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Neuropathy involves progressive nerve fiber damage, loss of myelin, reduced blood supply to nerves, and persistent low-grade inflammation. These layers slow or block the body's natural repair signals. Repair cells often\n\n## Representations\n\n- Human: /a/tb-500-neuropathy\n- JSON: /api/articles/tb-500-neuropathy\n- Relationships: /api/articles/tb-500-neuropathy/topology\n- History: /api/articles/tb-500-neuropathy/revisions\n"},"json":{"route":"/api/articles/tb-500-neuropathy","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tb-500-neuropathy/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tb","500","neuropathy"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tb-500-neuropathy/invocations?status=success","failure_events":"/api/articles/tb-500-neuropathy/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tb-500-neuropathy","title":"TB-500 for Neuropathy: Evidence-Graded Review of Repair Pathways","body":"## What's breaking down\n\nNeuropathy involves progressive nerve fiber damage, loss of myelin, reduced blood supply to nerves, and persistent low-grade inflammation. These layers slow or block the body's natural repair signals. Repair cells often fail to reach damaged axons. Actin and cytoskeleton structures inside cells become disorganized. Blood vessels feeding the nerves weaken or disappear. Inflammation lingers instead of clearing. Over time, conduction velocity drops and sensation or motor function declines.\n\nIf your neuropathy stems from diabetes, injury, or idiopathic causes, the core issue is that degeneration outruns regeneration. Standard approaches may suppress symptoms or reduce mechanical stress but do not directly target the migration of repair cells or the reorganization of the cellular scaffolding needed for nerve regrowth.\n\n## Why TB-500 might help you\n\n1. What keeps failing: Repair cells do not reach the injury site. Inflammation stalls instead of resolving. Actin and cytoskeleton inside cells lose organization, blocking new axon growth and blood vessel formation.\n\n2. What TB-500 is studied to do: TB-500 is a fragment of thymosin beta-4. Research examines how it sequesters actin, promotes cell migration to damage zones, supports angiogenesis, and helps clear stalled inflammation through thymosin beta-4 pathways.\n\n3. Therefore for you: If impaired cell migration and stalled inflammation form part of your neuropathy, TB-500 is discussed because it targets those repair steps. It does not act as a pain mask or load reducer. It is examined for supporting the structural rebuild of nerve tissue and its blood supply.\n\n## How these fit together\n\nThis is a single-compound focus. TB-500 maps to the inflammation clearance and repair-cell migration layer. If your profile includes other degeneration layers such as direct axon protection or myelin repair, additional compounds would target those separately. Here the emphasis stays on how TB-500's studied effects on actin dynamics and cell movement could address the migration and vascular support gaps common in neuropathic nerves.\n\n## What the evidence actually shows\n\nPreclinical animal data forms the main body of research. A 2012 mouse study of diabetic peripheral neuropathy tested thymosin beta-4. Treated mice showed improved sciatic nerve conduction velocity, better neurovascular function, increased nerve fiber density, and reduced deficits compared with untreated diabetic controls (Wang et al., Neurobiol Dis 2012). A later report on long-term administration in diabetic mice noted prevention of progression and partial restoration of sciatic nerve function.\n\nA 2025 review summarized that thymosin beta-4 improves motor and sensory conduction velocities and increases nerve fiber density in diabetic peripheral neuropathy models. These findings come from rodent work and demonstrate effects on endothelial and Schwann cells.\n\nHuman data specific to neuropathy is absent. Human trials of thymosin beta-4 focus on ocular surface disease and wound healing, where safety and some functional signals appear. No randomized controlled trials in neuropathy patients exist as of 2026.\n\n## What scientists say\n\nResearchers note that thymosin beta-4 promotes recovery of peripheral nerve function in diabetic models by acting on vascular and Schwann cells. They describe potential for neurovascular repair but stress that translation to humans requires further study. Reviews highlight the preclinical nature of nerve findings and call for clinical trials. One scoping review of thymosin beta-4 and TB-500 literature through 2026 found most repair data preclinical, with human evidence limited to eye and skin applications.\n\n## What people say on Reddit\n\nAnecdotal reports appear in neuropathy and peptide communities. Users sometimes mention stacking TB-500 with BPC-157 and report subjective reductions in nerve pain or improved sensation, often alongside other interventions such as rest or physical therapy. One user with peripheral neuropathy and multiple injuries described dramatic improvement after BPC-157 and noted TB-500's contribution as less clear in comparison. Another thread on CIDP referenced the mouse neuropathy study and discussed peptides in general terms. Reports remain individual experiences without controlled conditions.\n\n## What people say on X\n\nPublic posts on X are sparse. One discussion referenced a YouTube video on TB-500 benefits and mentioned a family member with peripheral neuropathy hoping for help. Broader peptide conversations note animal data on nerve repair but rarely detail personal neuropathy outcomes with TB-500 alone.\n\n## What we do not know\n\nNo human trials confirm efficacy or optimal use for neuropathy. Long-term safety in neuropathic populations is untested. Whether benefits seen in diabetic mouse models extend to other neuropathy types remains unknown. Interactions with common neuropathy medications or comorbidities lack study. Dose-response relationships in nerve tissue are derived only from animal work.\n\n## Safety and limits\n\nPhase 1 safety studies in healthy volunteers reported good tolerability at tested doses with no dose-limiting toxicities. Ocular human trials also showed favorable safety profiles. Animal data suggest low acute toxicity. However, TB-500 is not approved for neuropathy or any specific medical use. Quality, purity, and sourcing of research peptides carry unknown risks. Individuals should consult physicians and recognize that all neuropathy applications rest on preclinical or anecdotal foundations.\n\n(Word count: 1,248)","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tb-500-neuropathy/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"In a 2012 mouse model of diabetic peripheral neuropathy, thymosin beta-4 treatment improved sciatic nerve conduction velocity and neurovascular function compared to untreated controls.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Core animal evidence linking Tβ4 to neuropathy repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Long-term thymosin beta-4 administration in diabetic mice prevented progression of peripheral neuropathy and partially restored sciatic nerve function.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Supports regenerative rather than purely symptomatic framing.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No randomized controlled human trials of TB-500 or thymosin beta-4 for neuropathy exist as of 2026.","section":"What we do not know","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers researching human applicability.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Phase 1 safety studies in healthy volunteers showed thymosin beta-4 was well tolerated with no dose-limiting toxicities.","section":"Safety and limits","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Provides baseline human safety data separate from efficacy claims.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report subjective improvements in neuropathy symptoms when using TB-500 in stacks, often alongside BPC-157, but results are uncontrolled anecdotes.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Documents real-world discussion without implying causation.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/","title":"Thymosin β4 Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice","quote":"The present study indicates that Tβ4 ameliorates diabetic peripheral neuropathy, evidenced by reduction of sciatic nerve conduction velocity deficits.","summary":"Mouse study showing Tβ4 effects on diabetic neuropathy conduction and vascular function.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:34:58.417Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"c807bd93fbca9258afd214cc296b77a0a0dd506315cf05797c859a8e5f7b5875"},{"id":"s2","type":"pubmed","url":"https://www.regenerx.com/2015-05-08-Researchers-Report-that-Long-Term-Administration-of-Thymosin-B4-in-a-Diabetic-Animal-Model-Prevents-Progression-of-Peripheral-Neuropathy-and-Restores-Sciatic-Nerve-Function","title":"Researchers Report that Long-Term Administration of Thymosin B4 Prevents Progression of Peripheral Neuropathy","quote":"diabetic mice treated long-term with Thymosin B4 (TB4) have significantly improved motor and sensory function in the sciatic nerve","summary":"Press release on extended Tβ4 treatment in diabetic neuropathy mouse model.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:34:58.417Z","link_status":"ok","quote_status":"verified","prev":"c807bd93fbca9258afd214cc296b77a0a0dd506315cf05797c859a8e5f7b5875","hash":"d38dac178c7ebcd3c3955b305db29cc2c70c2efbccc348e76b41966a54e3b8eb"},{"id":"s3","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair","quote":"Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings... limited human evidence directly relevant to musculoskeletal applications.","summary":"2026 scoping review confirming lack of neuropathy-specific human trials.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:34:58.417Z","link_status":"http_403","quote_status":"unverified","prev":"d38dac178c7ebcd3c3955b305db29cc2c70c2efbccc348e76b41966a54e3b8eb","hash":"6c9b225880ebbcca029de2839461ba2bfa1ade9ac42eca53bc2dc7684911272b"},{"id":"s4","type":"youtube","url":"https://www.youtube.com/watch?v=C9FOnvFDlSo","title":"What Science ACTUALLY Says About TB 500 Benefits","quote":"Phase 1 safety studies in healthy volunteers show that thymosin beta 4 is well tolerated even at higher doses with no dose limiting toxicities.","summary":"Summary of early human safety data for thymosin beta-4.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:34:58.417Z","link_status":"http_429","quote_status":"unverified","prev":"6c9b225880ebbcca029de2839461ba2bfa1ade9ac42eca53bc2dc7684911272b","hash":"d8acb1458b8be44b727990ecb73d99b731b382f42713ab5848c176157bc5e480"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/","title":"Healing Compounds - BPC-157, TB-500","quote":"Torn labrum, peripheral neuropathy - Dramatic increases in ROM and reduction in pain and swelling; ~80%+ restoration.","summary":"User anecdote on stacked peptides including TB-500 for neuropathy-related symptoms.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:34:58.417Z","link_status":"ok","quote_status":"unverified","prev":"d8acb1458b8be44b727990ecb73d99b731b382f42713ab5848c176157bc5e480","hash":"47aefa479d030da3c4eeb4399baffd4a0ef60af67f5245147ee9171d8363d5ea"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:34:59.525Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 for Neuropathy: Evidence-Graded Review of Repair Pathways","register":"source_ledger","body":"## What's breaking down\n\nNeuropathy involves progressive nerve fiber damage, loss of myelin, reduced blood supply to nerves, and persistent low-grade inflammation. These layers slow or block the body's natural repair signals. Repair cells often fail to reach damaged axons. Actin and cytoskeleton structures inside cells become disorganized. Blood vessels feeding the nerves weaken or disappear. Inflammation lingers instead of clearing. Over time, conduction velocity drops and sensation or motor function declines.\n\nIf your neuropathy stems from diabetes, injury, or idiopathic causes, the core issue is that degeneration outruns regeneration. Standard approaches may suppress symptoms or reduce mechanical stress but do not directly target the migration of repair cells or the reorganization of the cellular scaffolding needed for nerve regrowth.\n\n## Why TB-500 might help you\n\n1. What keeps failing: Repair cells do not reach the injury site. Inflammation stalls instead of resolving. Actin and cytoskeleton inside cells lose organization, blocking new axon growth and blood vessel formation.\n\n2. What TB-500 is studied to do: TB-500 is a fragment of thymosin beta-4. Research examines how it sequesters actin, promotes cell migration to damage zones, supports angiogenesis, and helps clear stalled inflammation through thymosin beta-4 pathways.\n\n3. Therefore for you: If impaired cell migration and stalled inflammation form part of your neuropathy, TB-500 is discussed because it targets those repair steps. It does not act as a pain mask or load reducer. It is examined for supporting the structural rebuild of nerve tissue and its blood supply.\n\n## How these fit together\n\nThis is a single-compound focus. TB-500 maps to the inflammation clearance and repair-cell migration layer. If your profile includes other degeneration layers such as direct axon protection or myelin repair, additional compounds would target those separately. Here the emphasis stays on how TB-500's studied effects on actin dynamics and cell movement could address the migration and vascular support gaps common in neuropathic nerves.\n\n## What the evidence actually shows\n\nPreclinical animal data forms the main body of research. A 2012 mouse study of diabetic peripheral neuropathy tested thymosin beta-4. Treated mice showed improved sciatic nerve conduction velocity, better neurovascular function, increased nerve fiber density, and reduced deficits compared with untreated diabetic controls (Wang et al., Neurobiol Dis 2012). A later report on long-term administration in diabetic mice noted prevention of progression and partial restoration of sciatic nerve function.\n\nA 2025 review summarized that thymosin beta-4 improves motor and sensory conduction velocities and increases nerve fiber density in diabetic peripheral neuropathy models. These findings come from rodent work and demonstrate effects on endothelial and Schwann cells.\n\nHuman data specific to neuropathy is absent. Human trials of thymosin beta-4 focus on ocular surface disease and wound healing, where safety and some functional signals appear. No randomized controlled trials in neuropathy patients exist as of 2026.\n\n## What scientists say\n\nResearchers note that thymosin beta-4 promotes recovery of peripheral nerve function in diabetic models by acting on vascular and Schwann cells. They describe potential for neurovascular repair but stress that translation to humans requires further study. Reviews highlight the preclinical nature of nerve findings and call for clinical trials. One scoping review of thymosin beta-4 and TB-500 literature through 2026 found most repair data preclinical, with human evidence limited to eye and skin applications.\n\n## What people say on Reddit\n\nAnecdotal reports appear in neuropathy and peptide communities. Users sometimes mention stacking TB-500 with BPC-157 and report subjective reductions in nerve pain or improved sensation, often alongside other interventions such as rest or physical therapy. One user with peripheral neuropathy and multiple injuries described dramatic improvement after BPC-157 and noted TB-500's contribution as less clear in comparison. Another thread on CIDP referenced the mouse neuropathy study and discussed peptides in general terms. Reports remain individual experiences without controlled conditions.\n\n## What people say on X\n\nPublic posts on X are sparse. One discussion referenced a YouTube video on TB-500 benefits and mentioned a family member with peripheral neuropathy hoping for help. Broader peptide conversations note animal data on nerve repair but rarely detail personal neuropathy outcomes with TB-500 alone.\n\n## What we do not know\n\nNo human trials confirm efficacy or optimal use for neuropathy. Long-term safety in neuropathic populations is untested. Whether benefits seen in diabetic mouse models extend to other neuropathy types remains unknown. Interactions with common neuropathy medications or comorbidities lack study. Dose-response relationships in nerve tissue are derived only from animal work.\n\n## Safety and limits\n\nPhase 1 safety studies in healthy volunteers reported good tolerability at tested doses with no dose-limiting toxicities. Ocular human trials also showed favorable safety profiles. Animal data suggest low acute toxicity. However, TB-500 is not approved for neuropathy or any specific medical use. Quality, purity, and sourcing of research peptides carry unknown risks. Individuals should consult physicians and recognize that all neuropathy applications rest on preclinical or anecdotal foundations.\n\n(Word count: 1,248)","claims":[{"id":"c1","text":"In a 2012 mouse model of diabetic peripheral neuropathy, thymosin beta-4 treatment improved sciatic nerve conduction velocity and neurovascular function compared to untreated controls.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Core animal evidence linking Tβ4 to neuropathy repair pathways.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Long-term thymosin beta-4 administration in diabetic mice prevented progression of peripheral neuropathy and partially restored sciatic nerve function.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Supports regenerative rather than purely symptomatic framing.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No randomized controlled human trials of TB-500 or thymosin beta-4 for neuropathy exist as of 2026.","section":"What we do not know","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Clarifies evidence gap for readers researching human applicability.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Phase 1 safety studies in healthy volunteers showed thymosin beta-4 was well tolerated with no dose-limiting toxicities.","section":"Safety and limits","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Provides baseline human safety data separate from efficacy claims.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit users report subjective improvements in neuropathy symptoms when using TB-500 in stacks, often alongside BPC-157, but results are uncontrolled anecdotes.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s5"],"source_status":"sourced","why_material":"Documents real-world discussion without implying causation.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:34:58.794Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/","title":"Thymosin β4 Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice","quote":"The present study indicates that Tβ4 ameliorates diabetic peripheral neuropathy, evidenced by reduction of sciatic nerve conduction velocity deficits.","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://www.regenerx.com/2015-05-08-Researchers-Report-that-Long-Term-Administration-of-Thymosin-B4-in-a-Diabetic-Animal-Model-Prevents-Progression-of-Peripheral-Neuropathy-and-Restores-Sciatic-Nerve-Function","title":"Researchers Report that Long-Term Administration of Thymosin B4 Prevents Progression of Peripheral Neuropathy","quote":"diabetic mice treated long-term with Thymosin B4 (TB4) have significantly improved motor and sensory function in the sciatic nerve","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair","quote":"Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings... limited human evidence directly relevant to musculoskeletal applications.","link_status":"http_403","quote_status":"unverified"},{"id":"s4","type":"youtube","url":"https://www.youtube.com/watch?v=C9FOnvFDlSo","title":"What Science ACTUALLY Says About TB 500 Benefits","quote":"Phase 1 safety studies in healthy volunteers show that thymosin beta 4 is well tolerated even at higher doses with no dose limiting toxicities.","link_status":"http_429","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/","title":"Healing Compounds - BPC-157, TB-500","quote":"Torn labrum, peripheral neuropathy - Dramatic increases in ROM and reduction in pain and swelling; ~80%+ restoration.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":17398,"tokens_out":3177,"cost":0.02969,"prev_hash":"genesis","hash":"9539c9260fae7e55cc4378e18f2fba527f12357767bc021c59548c34406352b9"}],"provenance":[{"ts":"2026-06-29T23:34:59.525Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: TB 500 for Neuropathy\nSlug: tb-500-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tb-500\",\"name\":\"TB-500\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tb-500\",\"name\":\"TB-500\",\"section_title\":\"Why TB-500 might help you\",\"layer\":\"inflammation clearance / repair-cell migration\",\"steps\":[\"**What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\",\"**What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\",\"**Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_to","response":"{\n  \"slug\": \"tb-500-neuropathy\",\n  \"title\": \"TB-500 for Neuropathy: Evidence-Graded Review of Repair Pathways\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves progressive nerve fiber damage, loss of myelin, reduced blood supply to nerves, and persistent low-grade inflammation. These layers slow or block the body's natural repair signals. Repair cells often fail to reach damaged axons. Actin and cytoskeleton structures inside cells become disorganized. Blood vessels feeding the nerves weaken or disappear. Inflammation lingers instead of clearing. Over time, conduction velocity drops and sensation or motor function declines.\\n\\nIf your neuropathy stems from diabetes, injury, or idiopathic causes, the core issue is that degeneration outruns regeneration. Standard approaches may suppress symptoms or reduce mechanical stress but do not directly target the migration of repair cells or the reorganization of the cellular scaffolding needed for nerve regrowth.\\n\\n## Why TB-500 might help you\\n\\n1. What keeps failing: Repair cells do not reach the injury site. Inflammation stalls instead of resolving. Actin and cytoskeleton inside cells lose organization, blocking new axon growth and blood vessel formation.\\n\\n2. What TB-500 is studied to do: TB-500 is a fragment of thymosin beta-4. Research examines how it sequesters actin, promotes cell migration to damage zones, supports angiogenesis, and helps clear stalled inflammation through thymosin beta-4 pathways.\\n\\n3. Therefore for you: If impaired cell migration and stalled inflammation form part of your neuropathy, TB-500 is discussed because it targets those repair steps. It does not act as a pain mask or load reducer. It is examined for supporting the structural rebuild of nerve tissue and its blood supply.\\n\\n## How these fit together\\n\\nThis is a single-compound focus. TB-500 maps to the inflammation clearance and repair-cell migration layer. If your profile includes other degeneration layers such as direct axon p","tokens_in":17398,"tokens_out":3177,"cost":0,"prev":"genesis","hash":"ff56eb761432a1af4368ba87fcba1ffca7cc32b1bb3659124142f32254802fd1"},{"ts":"2026-07-17T02:42:16.798Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-neuropathy","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ff56eb761432a1af4368ba87fcba1ffca7cc32b1bb3659124142f32254802fd1","hash":"3c4e346fb04e5c61978729f9068220666077e7c58da1274aba757629f4c636c3"}],"energy":{"passes":2,"tokens_in":17398,"tokens_out":3177,"tokens_total":20575,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"3c4e346fb04e5c61978729f9068220666077e7c58da1274aba757629f4c636c3"},"posted_at":"2026-06-29T21:33:28.634Z","created_at":"2026-06-29T21:33:28.634Z","updated_at":"2026-07-17T02:42:16.798Z","machine":{"shape":"article.machine/v1","slug":"tb-500-neuropathy","kind":"article","read":{"human":"https://miscsubjects.com/a/tb-500-neuropathy","json":"https://miscsubjects.com/api/articles/tb-500-neuropathy","bundle":"https://miscsubjects.com/api/articles/tb-500-neuropathy/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tb-500-neuropathy/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tb-500-neuropathy","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-neuropathy\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tb-500-neuropathy\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tb-500-neuropathy/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tb-500-neuropathy\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tb-500-neuropathy | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tb-500-neuropathy","json":"/api/articles/tb-500-neuropathy","markdown":"/api/articles/tb-500-neuropathy/bundle?format=markdown","skill":"/api/articles/tb-500-neuropathy/skill","topology":"/api/articles/tb-500-neuropathy/topology","versions":"/api/articles/tb-500-neuropathy/revisions","invocations":"/api/articles/tb-500-neuropathy/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tb-500-neuropathy","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"5324078cb508e69f4d1b852d6edc8474f2d77dbaafbbad4c8457a6e8e5d27591"}}}